Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases

Tina J Hieken, Salve G. Ronan, Miguel Farolan, Anne L. Shilkaitis, Dong K. Kim, Tapas K. Das Gupta

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background Elective lymph node dissection for malignant melanoma is still controversial. Experimental studies suggest that differential expression, activation, or both of β1 integrins facilitate melanoma metastases. However, the clinical significance of β1 integrin expression in human melanoma is unclear. Methods We examined primary cutaneous melanomas from 76 patients undergoing elective lymph node dissection. We quantified the percentage of tumor area stained by β1 integrin antibody with an image analyzer. Results β1 integrin was expressed in all 23 primary tumors from patients with pathologically positive lymph nodes (LNs) but in only 14 (26%) of 53 cases with pathologically negative nodes (p<0.001). No patients with β1 integrin-negative tumors had LN involvement, whereas 23 (62%) of 37 patients with β1 integrin-positive tumors had LN metastases (p<0.001). Furthermore, 21 (91%) of 23 cases with LN metastases but only 4 (8%) of 53 cases without had β1 integrin staining of 10% or more of tumor area (p<0.001). Conclusions Our study is the first to show a correlation between expression of a molecular marker in the primary cutaneous melanoma and likelihood of regional LN metastases. β1 immunostaining of 10% or more of tumor area reliably predicts patients most likely to harbor occult LN metastases and likely to benefit from ELND.

Original languageEnglish (US)
Pages (from-to)669-675
Number of pages7
JournalSurgery
Volume118
Issue number4
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

CD29 Antigens
Integrins
Melanoma
Lymph Nodes
Neoplasm Metastasis
Neoplasms
Lymph Node Excision
Skin
Staining and Labeling

ASJC Scopus subject areas

  • Surgery

Cite this

Hieken, T. J., Ronan, S. G., Farolan, M., Shilkaitis, A. L., Kim, D. K., & Das Gupta, T. K. (1995). Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases. Surgery, 118(4), 669-675. https://doi.org/10.1016/S0039-6060(05)80034-0

Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases. / Hieken, Tina J; Ronan, Salve G.; Farolan, Miguel; Shilkaitis, Anne L.; Kim, Dong K.; Das Gupta, Tapas K.

In: Surgery, Vol. 118, No. 4, 1995, p. 669-675.

Research output: Contribution to journalArticle

Hieken, TJ, Ronan, SG, Farolan, M, Shilkaitis, AL, Kim, DK & Das Gupta, TK 1995, 'Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases', Surgery, vol. 118, no. 4, pp. 669-675. https://doi.org/10.1016/S0039-6060(05)80034-0
Hieken, Tina J ; Ronan, Salve G. ; Farolan, Miguel ; Shilkaitis, Anne L. ; Kim, Dong K. ; Das Gupta, Tapas K. / Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases. In: Surgery. 1995 ; Vol. 118, No. 4. pp. 669-675.
@article{e5faf7b9edec433890f4932fd372bb7e,
title = "Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases",
abstract = "Background Elective lymph node dissection for malignant melanoma is still controversial. Experimental studies suggest that differential expression, activation, or both of β1 integrins facilitate melanoma metastases. However, the clinical significance of β1 integrin expression in human melanoma is unclear. Methods We examined primary cutaneous melanomas from 76 patients undergoing elective lymph node dissection. We quantified the percentage of tumor area stained by β1 integrin antibody with an image analyzer. Results β1 integrin was expressed in all 23 primary tumors from patients with pathologically positive lymph nodes (LNs) but in only 14 (26{\%}) of 53 cases with pathologically negative nodes (p<0.001). No patients with β1 integrin-negative tumors had LN involvement, whereas 23 (62{\%}) of 37 patients with β1 integrin-positive tumors had LN metastases (p<0.001). Furthermore, 21 (91{\%}) of 23 cases with LN metastases but only 4 (8{\%}) of 53 cases without had β1 integrin staining of 10{\%} or more of tumor area (p<0.001). Conclusions Our study is the first to show a correlation between expression of a molecular marker in the primary cutaneous melanoma and likelihood of regional LN metastases. β1 immunostaining of 10{\%} or more of tumor area reliably predicts patients most likely to harbor occult LN metastases and likely to benefit from ELND.",
author = "Hieken, {Tina J} and Ronan, {Salve G.} and Miguel Farolan and Shilkaitis, {Anne L.} and Kim, {Dong K.} and {Das Gupta}, {Tapas K.}",
year = "1995",
doi = "10.1016/S0039-6060(05)80034-0",
language = "English (US)",
volume = "118",
pages = "669--675",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases

AU - Hieken, Tina J

AU - Ronan, Salve G.

AU - Farolan, Miguel

AU - Shilkaitis, Anne L.

AU - Kim, Dong K.

AU - Das Gupta, Tapas K.

PY - 1995

Y1 - 1995

N2 - Background Elective lymph node dissection for malignant melanoma is still controversial. Experimental studies suggest that differential expression, activation, or both of β1 integrins facilitate melanoma metastases. However, the clinical significance of β1 integrin expression in human melanoma is unclear. Methods We examined primary cutaneous melanomas from 76 patients undergoing elective lymph node dissection. We quantified the percentage of tumor area stained by β1 integrin antibody with an image analyzer. Results β1 integrin was expressed in all 23 primary tumors from patients with pathologically positive lymph nodes (LNs) but in only 14 (26%) of 53 cases with pathologically negative nodes (p<0.001). No patients with β1 integrin-negative tumors had LN involvement, whereas 23 (62%) of 37 patients with β1 integrin-positive tumors had LN metastases (p<0.001). Furthermore, 21 (91%) of 23 cases with LN metastases but only 4 (8%) of 53 cases without had β1 integrin staining of 10% or more of tumor area (p<0.001). Conclusions Our study is the first to show a correlation between expression of a molecular marker in the primary cutaneous melanoma and likelihood of regional LN metastases. β1 immunostaining of 10% or more of tumor area reliably predicts patients most likely to harbor occult LN metastases and likely to benefit from ELND.

AB - Background Elective lymph node dissection for malignant melanoma is still controversial. Experimental studies suggest that differential expression, activation, or both of β1 integrins facilitate melanoma metastases. However, the clinical significance of β1 integrin expression in human melanoma is unclear. Methods We examined primary cutaneous melanomas from 76 patients undergoing elective lymph node dissection. We quantified the percentage of tumor area stained by β1 integrin antibody with an image analyzer. Results β1 integrin was expressed in all 23 primary tumors from patients with pathologically positive lymph nodes (LNs) but in only 14 (26%) of 53 cases with pathologically negative nodes (p<0.001). No patients with β1 integrin-negative tumors had LN involvement, whereas 23 (62%) of 37 patients with β1 integrin-positive tumors had LN metastases (p<0.001). Furthermore, 21 (91%) of 23 cases with LN metastases but only 4 (8%) of 53 cases without had β1 integrin staining of 10% or more of tumor area (p<0.001). Conclusions Our study is the first to show a correlation between expression of a molecular marker in the primary cutaneous melanoma and likelihood of regional LN metastases. β1 immunostaining of 10% or more of tumor area reliably predicts patients most likely to harbor occult LN metastases and likely to benefit from ELND.

UR - http://www.scopus.com/inward/record.url?scp=0028970691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028970691&partnerID=8YFLogxK

U2 - 10.1016/S0039-6060(05)80034-0

DO - 10.1016/S0039-6060(05)80034-0

M3 - Article

C2 - 7570321

AN - SCOPUS:0028970691

VL - 118

SP - 669

EP - 675

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 4

ER -